JOT's CEO, Christer Rosén, will be attending the 13th Annual BioExec Institute Retreat on March 29-April 1 in Palm Beach, FL!
Press Release: Catalent to develop softgel capsules for JOT's leading orphan disease candidates!
Read article here! 
Press Release: Professor Li-Huei Tsai, Ph.D., Professor Scott Turner, Ph.D., and Robert Hahl, Ph.D. join JOT!
CEO Christer Rosén will be attending the 2016 Boston CEO Conference May 31-June 1, 2016
Press Release: David Sinclair, Ph.D. joins JOT
FARA includes JOT101 on their FA Treatment Pipeline - January 2016.
JOT initiates collaboration with the Friedreich's Ataxia Research Alliance (FARA).
JOT participated in the 2016 Noble Financial Conference in Port St. Lucie, FL, USA.
|
Press Release: Jupiter Orphan Therapeutics Secures Financing and Adds Board Member!
Read article here! 
Jupiter Orphan Therapeutics, Inc featured in Wall Street Journal!
Press Release: JOT enters into a Global Licensing Agreement with Murdoch Childrens Research Institute for development of treatment for Friedreich's Ataxia!
JOT launches Facebook and Twitter pages! Go in and follow @JupiterOrphan and like our Facebook page!
JOT moves domicile to Delaware on January 1, 2016 with operations in Jupiter, FL.
Cooley, LLP engaged as corporate council.
JOT participated in the November 2015 NJ/NYC CEO Biotech Conference in New York, NY, USA.
|
